Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 172

1.

Healthcare utilization and productivity loss in glioma patients and family caregivers: the impact of treatable psychological symptoms.

Boele FW, Meads D, Jansen F, Verdonck-de Leeuw IM, Heimans JJ, Reijneveld JC, Short SC, Klein M.

J Neurooncol. 2020 Mar 14. doi: 10.1007/s11060-020-03454-3. [Epub ahead of print]

PMID:
32172441
2.

International standards for the analysis of quality-of-life and patient-reported outcome endpoints in cancer randomised controlled trials: recommendations of the SISAQOL Consortium.

Coens C, Pe M, Dueck AC, Sloan J, Basch E, Calvert M, Campbell A, Cleeland C, Cocks K, Collette L, Devlin N, Dorme L, Flechtner HH, Gotay C, Griebsch I, Groenvold M, King M, Kluetz PG, Koller M, Malone DC, Martinelli F, Mitchell SA, Musoro JZ, O'Connor D, Oliver K, Piault-Louis E, Piccart M, Quinten C, Reijneveld JC, Schürmann C, Smith AW, Soltys KM, Taphoorn MJB, Velikova G, Bottomley A; Setting International Standards in Analyzing Patient-Reported Outcomes and Quality of Life Endpoints Data Consortium.

Lancet Oncol. 2020 Feb;21(2):e83-e96. doi: 10.1016/S1470-2045(19)30790-9. Review.

PMID:
32007209
3.

Postoperative oscillatory brain activity as an add-on prognostic marker in diffuse glioma.

Belgers V, Numan T, Kulik SD, Hillebrand A, de Witt Hamer PC, Geurts JJG, Reijneveld JC, Wesseling P, Klein M, Derks J, Douw L.

J Neurooncol. 2020 Mar;147(1):49-58. doi: 10.1007/s11060-019-03386-7. Epub 2020 Jan 17.

4.

Symptom clusters in newly diagnosed glioma patients: which symptom clusters are independently associated with functioning and global health status?

Coomans MB, Dirven L, Aaronson NK, Baumert BG, Van Den Bent M, Bottomley A, Brandes AA, Chinot O, Coens C, Gorlia T, Herrlinger U, Keime-Guibert F, Malmström A, Martinelli F, Stupp R, Talacchi A, Weller M, Wick W, Reijneveld JC, Taphoorn MJB.

Neuro Oncol. 2019 Nov 4;21(11):1447-1457. doi: 10.1093/neuonc/noz118.

5.

Efficacy and cost-utility of the eHealth application 'Oncokompas', supporting patients with incurable cancer in finding optimal palliative care, tailored to their quality of life and personal preferences: a study protocol of a randomized controlled trial.

Schuit AS, Holtmaat K, Hooghiemstra N, Jansen F, Lissenberg-Witte BI, Coupé VMH, van Linde ME, Becker-Commissaris A, Reijneveld JC, Zijlstra JM, Sommeijer DW, Eerenstein SEJ, Verdonck-de Leeuw IM.

BMC Palliat Care. 2019 Oct 23;18(1):85. doi: 10.1186/s12904-019-0468-8.

6.

Current state of quality of life and patient-reported outcomes research.

Bottomley A, Reijneveld JC, Koller M, Flechtner H, Tomaszewski KA, Greimel E; 5th EORTC Quality of Life in Cancer Clinical Trials Conference Faculty.

Eur J Cancer. 2019 Nov;121:55-63. doi: 10.1016/j.ejca.2019.08.016. Epub 2019 Sep 24.

7.

Improved detection of diffuse glioma infiltration with imaging combinations: a diagnostic accuracy study.

Verburg N, Koopman T, Yaqub MM, Hoekstra OS, Lammertsma AA, Barkhof F, Pouwels PJW, Reijneveld JC, Heimans JJ, Rozemuller AJM, Bruynzeel AME, Lagerwaard F, Vandertop WP, Boellaard R, Wesseling P, de Witt Hamer PC.

Neuro Oncol. 2020 Mar 5;22(3):412-422. doi: 10.1093/neuonc/noz180.

8.

Direct comparison of [11C] choline and [18F] FET PET to detect glioma infiltration: a diagnostic accuracy study in eight patients.

Verburg N, Koopman T, Yaqub M, Hoekstra OS, Lammertsma AA, Schwarte LA, Barkhof F, Pouwels PJW, Heimans JJ, Reijneveld JC, Rozemuller AJM, Vandertop WP, Wesseling P, Boellaard R, de Witt Hamer PC.

EJNMMI Res. 2019 Jun 28;9(1):57. doi: 10.1186/s13550-019-0523-8.

9.

Advance care planning in glioblastoma patients: development of a disease-specific ACP program.

Fritz L, Zwinkels H, Koekkoek JAF, Reijneveld JC, Vos MJ, Dirven L, Pasman HRW, Taphoorn MJB.

Support Care Cancer. 2020 Mar;28(3):1315-1324. doi: 10.1007/s00520-019-04916-9. Epub 2019 Jun 26.

10.

The added value of health-related quality of life as a prognostic indicator of overall survival and progression-free survival in glioma patients: a meta-analysis based on individual patient data from randomised controlled trials.

Coomans M, Dirven L, K Aaronson N, Baumert BG, van den Bent M, Bottomley A, Brandes AA, Chinot O, Coens C, Gorlia T, Herrlinger U, Keime-Guibert F, Malmström A, Martinelli F, Stupp R, Talacchi A, Weller M, Wick W, Reijneveld JC, Taphoorn MJB; EORTC Quality of Life Group and the EORTC Brain Tumor Group.

Eur J Cancer. 2019 Jul;116:190-198. doi: 10.1016/j.ejca.2019.05.012. Epub 2019 Jun 13.

PMID:
31203194
11.

Evaluation of the content coverage of questionnaires containing basic and instrumental activities of daily living (ADL) used in adult patients with brain tumors.

Oort Q, Taphoorn MJB, Sikkes SAM, Uitdehaag BMJ, Reijneveld JC, Dirven L.

J Neurooncol. 2019 May;143(1):1-13. doi: 10.1007/s11060-019-03136-9. Epub 2019 Mar 18.

12.

Understanding cognitive functioning in glioma patients: The relevance of IDH-mutation status and functional connectivity.

Derks J, Kulik S, Wesseling P, Numan T, Hillebrand A, van Dellen E, de Witt Hamer PC, Geurts JJG, Reijneveld JC, Stam CJ, Klein M, Douw L.

Brain Behav. 2019 Apr;9(4):e01204. doi: 10.1002/brb3.1204. Epub 2019 Feb 26.

13.

Withdrawal of antiepileptic drugs in patients with low grade and anaplastic glioma after long-term seizure freedom: a prospective observational study.

Kerkhof M, Koekkoek JAF, Vos MJ, van den Bent MJ, Taal W, Postma TJ, Bromberg JEC, Kouwenhoven MCM, Dirven L, Reijneveld JC, Taphoorn MJB.

J Neurooncol. 2019 May;142(3):463-470. doi: 10.1007/s11060-019-03117-y. Epub 2019 Feb 18.

14.

The association between preoperative edema and postoperative cognitive functioning and health-related quality of life in WHO grade I meningioma patients.

van Nieuwenhuizen D, Slot KM, Klein M, Verbaan D, Aliaga ES, Heimans JJ, Vandertop WP, Peerdeman SM, Reijneveld JC.

Acta Neurochir (Wien). 2019 Mar;161(3):579-588. doi: 10.1007/s00701-019-03819-2. Epub 2019 Feb 13.

15.

Impact of Radiation Target Volume on Health-Related Quality of Life in Patients With Low-Grade Glioma in the 2-Year Period Post Treatment: A Secondary Analysis of the EORTC 22033-26033.

Dirven L, Reijneveld JC, Taphoorn MJB, Coens C, El-Badawy SA, Tzuk-Shina T, Bravo-Marques J, Back M, Stalpers LJA, Stupp R, Baumert BG, Seidel C.

Int J Radiat Oncol Biol Phys. 2019 May 1;104(1):90-100. doi: 10.1016/j.ijrobp.2019.01.003. Epub 2019 Feb 2.

PMID:
30716525
16.

Cognitive functioning and functional brain networks in postoperative WHO grade I meningioma patients.

van Nieuwenhuizen D, Douw L, Klein M, Peerdeman SM, Heimans JJ, Reijneveld JC, Stam CJ, Hillebrand A.

J Neurooncol. 2018 Dec;140(3):605-613. doi: 10.1007/s11060-018-2987-1. Epub 2018 Sep 15.

17.

Statistical analysis of patient-reported outcome data in randomised controlled trials of locally advanced and metastatic breast cancer: a systematic review.

Pe M, Dorme L, Coens C, Basch E, Calvert M, Campbell A, Cleeland C, Cocks K, Collette L, Dirven L, Dueck AC, Devlin N, Flechtner HH, Gotay C, Griebsch I, Groenvold M, King M, Koller M, Malone DC, Martinelli F, Mitchell SA, Musoro JZ, Oliver K, Piault-Louis E, Piccart M, Pimentel FL, Quinten C, Reijneveld JC, Sloan J, Velikova G, Bottomley A; Setting International Standards in Analyzing Patient-Reported Outcomes and Quality of Life Endpoints Data Consortium (SISAQOL).

Lancet Oncol. 2018 Sep;19(9):e459-e469. doi: 10.1016/S1470-2045(18)30418-2.

18.

Moving forward toward standardizing analysis of quality of life data in randomized cancer clinical trials.

Bottomley A, Pe M, Sloan J, Basch E, Bonnetain F, Calvert M, Campbell A, Cleeland C, Cocks K, Collette L, Dueck AC, Devlin N, Flechtner HH, Gotay C, Greimel E, Griebsch I, Groenvold M, Hamel JF, King M, Kluetz PG, Koller M, Malone DC, Martinelli F, Mitchell SA, Moinpour CM, Musoro JZ, O'Connor D, Oliver K, Piault-Louis E, Piccart M, Pimentel FL, Quinten C, Reijneveld JC, Schürmann C, Smith AW, Soltys KM, Sridhara R, Taphoorn MJB, Velikova G, Coens C.

Clin Trials. 2018 Dec;15(6):624-630. doi: 10.1177/1740774518795637. Epub 2018 Aug 24.

19.

Localization of the Epileptogenic Zone Using Interictal MEG and Machine Learning in a Large Cohort of Drug-Resistant Epilepsy Patients.

Nissen IA, Stam CJ, van Straaten ECW, Wottschel V, Reijneveld JC, Baayen JC, de Witt Hamer PC, Idema S, Velis DN, Hillebrand A.

Front Neurol. 2018 Aug 7;9:647. doi: 10.3389/fneur.2018.00647. eCollection 2018.

20.

Bevacizumab and temozolomide in patients with first recurrence of WHO grade II and III glioma, without 1p/19q co-deletion (TAVAREC): a randomised controlled phase 2 EORTC trial.

van den Bent MJ, Klein M, Smits M, Reijneveld JC, French PJ, Clement P, de Vos FYF, Wick A, Mulholland PJ, Taphoorn MJB, Lewis J, Weller M, Chinot OL, Kros JM, de Heer I, Verschuere T, Coens C, Golfinopoulos V, Gorlia T, Idbaih A.

Lancet Oncol. 2018 Sep;19(9):1170-1179. doi: 10.1016/S1470-2045(18)30362-0. Epub 2018 Aug 13.

PMID:
30115593
21.

Oscillatory brain activity associates with neuroligin-3 expression and predicts progression free survival in patients with diffuse glioma.

Derks J, Wesseling P, Carbo EWS, Hillebrand A, van Dellen E, de Witt Hamer PC, Klein M, Schenk GJ, Geurts JJG, Reijneveld JC, Douw L.

J Neurooncol. 2018 Nov;140(2):403-412. doi: 10.1007/s11060-018-2967-5. Epub 2018 Aug 9.

22.

The EORTC CAT Core-The computer adaptive version of the EORTC QLQ-C30 questionnaire.

Petersen MA, Aaronson NK, Arraras JI, Chie WC, Conroy T, Costantini A, Dirven L, Fayers P, Gamper EM, Giesinger JM, Habets EJJ, Hammerlid E, Helbostad J, Hjermstad MJ, Holzner B, Johnson C, Kemmler G, King MT, Kaasa S, Loge JH, Reijneveld JC, Singer S, Taphoorn MJB, Thamsborg LH, Tomaszewski KA, Velikova G, Verdonck-de Leeuw IM, Young T, Groenvold M; European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Group.

Eur J Cancer. 2018 Sep;100:8-16. doi: 10.1016/j.ejca.2018.04.016. Epub 2018 Jun 21.

23.

Understanding the quality of life (QOL) issues in survivors of cancer: towards the development of an EORTC QOL cancer survivorship questionnaire.

van Leeuwen M, Husson O, Alberti P, Arraras JI, Chinot OL, Costantini A, Darlington AS, Dirven L, Eichler M, Hammerlid EB, Holzner B, Johnson CD, Kontogianni M, Kjær TK, Morag O, Nolte S, Nordin A, Pace A, Pinto M, Polz K, Ramage J, Reijneveld JC, Serpentini S, Tomaszewski KA, Vassiliou V, Verdonck-de Leeuw IM, Vistad I, Young TE, Aaronson NK, van de Poll-Franse LV; EORTC QLG.

Health Qual Life Outcomes. 2018 Jun 4;16(1):114. doi: 10.1186/s12955-018-0920-0.

24.

Working plan for the use of patient-reported outcome measures in adults with brain tumours: a Response Assessment in Neuro-Oncology (RANO) initiative.

Dirven L, Armstrong TS, Blakeley JO, Brown PD, Grant R, Jalali R, Leeper H, Mendoza T, Nayak L, Reijneveld JC, Le Rhun E, Walbert T, Weller M, Wen PY, Taphoorn MJB.

Lancet Oncol. 2018 Mar;19(3):e173-e180. doi: 10.1016/S1470-2045(18)30004-4. Review.

PMID:
29508764
25.

The DNA methylome of DDR genes and benefit from RT or TMZ in IDH mutant low-grade glioma treated in EORTC 22033.

Bady P, Kurscheid S, Delorenzi M, Gorlia T, van den Bent MJ, Hoang-Xuan K, Vauléon É, Gijtenbeek A, Enting R, Thiessen B, Chinot O, Dhermain F, Brandes AA, Reijneveld JC, Marosi C, Taphoorn MJB, Wick W, von Deimling A, French P, Stupp R, Baumert BG, Hegi ME.

Acta Neuropathol. 2018 Apr;135(4):601-615. doi: 10.1007/s00401-018-1810-6. Epub 2018 Jan 24.

26.

Internet-based guided self-help for glioma patients with depressive symptoms: a randomized controlled trial.

Boele FW, Klein M, Verdonck-de Leeuw IM, Cuijpers P, Heimans JJ, Snijders TJ, Vos M, Bosma I, Tijssen CC, Reijneveld JC; Dutch Society for Neuro-Oncology (LWNO).

J Neurooncol. 2018 Mar;137(1):191-203. doi: 10.1007/s11060-017-2712-5. Epub 2017 Dec 13.

27.

Diagnostic Accuracy of Neuroimaging to Delineate Diffuse Gliomas within the Brain: A Meta-Analysis.

Verburg N, Hoefnagels FWA, Barkhof F, Boellaard R, Goldman S, Guo J, Heimans JJ, Hoekstra OS, Jain R, Kinoshita M, Pouwels PJW, Price SJ, Reijneveld JC, Stadlbauer A, Vandertop WP, Wesseling P, Zwinderman AH, De Witt Hamer PC.

AJNR Am J Neuroradiol. 2017 Oct;38(10):1884-1891. doi: 10.3174/ajnr.A5368. Epub 2017 Sep 7.

28.

Development of an item bank for computerized adaptive testing of self-reported cognitive difficulty in cancer patients.

Dirven L, Taphoorn MJ, Groenvold M, Habets EJ, Aaronson NK, Conroy T, Reijneveld JC, Young T, Petersen MA; EORTC Quality of Life Group.

Neurooncol Pract. 2017 Sep;4(3):189-196. doi: 10.1093/nop/npw026. Epub 2017 Jan 19.

29.

Swarm Intelligence-Enhanced Detection of Non-Small-Cell Lung Cancer Using Tumor-Educated Platelets.

Best MG, Sol N, In 't Veld SGJG, Vancura A, Muller M, Niemeijer AN, Fejes AV, Tjon Kon Fat LA, Huis In 't Veld AE, Leurs C, Le Large TY, Meijer LL, Kooi IE, Rustenburg F, Schellen P, Verschueren H, Post E, Wedekind LE, Bracht J, Esenkbrink M, Wils L, Favaro F, Schoonhoven JD, Tannous J, Meijers-Heijboer H, Kazemier G, Giovannetti E, Reijneveld JC, Idema S, Killestein J, Heger M, de Jager SC, Urbanus RT, Hoefer IE, Pasterkamp G, Mannhalter C, Gomez-Arroyo J, Bogaard HJ, Noske DP, Vandertop WP, van den Broek D, Ylstra B, Nilsson RJA, Wesseling P, Karachaliou N, Rosell R, Lee-Lewandrowski E, Lewandrowski KB, Tannous BA, de Langen AJ, Smit EF, van den Heuvel MM, Wurdinger T.

Cancer Cell. 2017 Aug 14;32(2):238-252.e9. doi: 10.1016/j.ccell.2017.07.004.

30.

Evidence-based management of adult patients with diffuse glioma - Authors' reply.

Weller M, van den Bent M, Tonn JC, Stupp R, Preusser M, Cohen-Jonathan-Moyal E, Henriksson R, Rhun EL, Balana C, Chinot O, Bendszus M, Reijneveld JC, Dhermain F, French P, Marosi C, Watts C, Oberg I, Pilkington G, Baumert BG, Taphoorn MJB, Hegi M, Westphal M, Reifenberger G, Soffietti R, Wick W; European Association for Neuro-Oncology (EANO) Task Force on Gliomas.

Lancet Oncol. 2017 Aug;18(8):e430-e431. doi: 10.1016/S1470-2045(17)30515-6. Epub 2017 Jul 26. No abstract available.

31.

Treatment outcome of patients with recurrent glioblastoma multiforme: a retrospective multicenter analysis.

van Linde ME, Brahm CG, de Witt Hamer PC, Reijneveld JC, Bruynzeel AME, Vandertop WP, van de Ven PM, Wagemakers M, van der Weide HL, Enting RH, Walenkamp AME, Verheul HMW.

J Neurooncol. 2017 Oct;135(1):183-192. doi: 10.1007/s11060-017-2564-z. Epub 2017 Jul 20.

32.

European Association for Neuro-Oncology (EANO) guideline on the diagnosis and treatment of adult astrocytic and oligodendroglial gliomas.

Weller M, van den Bent M, Tonn JC, Stupp R, Preusser M, Cohen-Jonathan-Moyal E, Henriksson R, Rhun EL, Balana C, Chinot O, Bendszus M, Reijneveld JC, Dhermain F, French P, Marosi C, Watts C, Oberg I, Pilkington G, Baumert BG, Taphoorn MJB, Hegi M, Westphal M, Reifenberger G, Soffietti R, Wick W; European Association for Neuro-Oncology (EANO) Task Force on Gliomas.

Lancet Oncol. 2017 Jun;18(6):e315-e329. doi: 10.1016/S1470-2045(17)30194-8. Epub 2017 May 5. Review. Erratum in: Lancet Oncol. 2017 Nov;18(11):e642.

33.

Dynamic hub load predicts cognitive decline after resective neurosurgery.

Carbo EW, Hillebrand A, van Dellen E, Tewarie P, de Witt Hamer PC, Baayen JC, Klein M, Geurts JJ, Reijneveld JC, Stam CJ, Douw L.

Sci Rep. 2017 Feb 7;7:42117. doi: 10.1038/srep42117.

34.

Connectomic profile and clinical phenotype in newly diagnosed glioma patients.

Derks J, Dirkson AR, de Witt Hamer PC, van Geest Q, Hulst HE, Barkhof F, Pouwels PJ, Geurts JJ, Reijneveld JC, Douw L.

Neuroimage Clin. 2017 Jan 16;14:87-96. doi: 10.1016/j.nicl.2017.01.007. eCollection 2017.

35.

Focusing on Core Patient-Reported Outcomes in Cancer Clinical Trials-Letter.

Groenvold M, Aaronson NK, Darlington AE, Fitzsimmons D, Greimel E, Holzner B, Reijneveld JC, Tomaszewski KA, Verdonck-de Leeuw I, van de Poll-Franse L; EORTC Quality of Life Group.

Clin Cancer Res. 2016 Nov 15;22(22):5617. doi: 10.1158/1078-0432.CCR-16-1529. No abstract available.

36.

Development of a questionnaire measuring instrumental activities of daily living (IADL) in patients with brain tumors: a pilot study.

Oort Q, Dirven L, Meijer W, Sikkes SA, Uitdehaag BM, Reijneveld JC, Taphoorn MJ.

J Neurooncol. 2017 Mar;132(1):145-153. doi: 10.1007/s11060-016-2352-1. Epub 2017 Feb 1.

37.

Prevalence of changes in personality and behavior in adult glioma patients: a systematic review.

Zwinkels H, Dirven L, Vissers T, Habets EJJ, Vos MJ, Reijneveld JC, van den Bent MJ, Taphoorn MJB.

Neurooncol Pract. 2016 Dec;3(4):222-231. doi: 10.1093/nop/npv040. Epub 2015 Sep 29. Review.

38.

Identifying the epileptogenic zone in interictal resting-state MEG source-space networks.

Nissen IA, Stam CJ, Reijneveld JC, van Straaten IE, Hendriks EJ, Baayen JC, De Witt Hamer PC, Idema S, Hillebrand A.

Epilepsia. 2017 Jan;58(1):137-148. doi: 10.1111/epi.13622. Epub 2016 Nov 26.

39.

Advance Care Planning in Glioblastoma Patients.

Fritz L, Dirven L, Reijneveld JC, Koekkoek JA, Stiggelbout AM, Pasman HR, Taphoorn MJ.

Cancers (Basel). 2016 Nov 8;8(11). pii: E102. Review.

40.

Analysing data from patient-reported outcome and quality of life endpoints for cancer clinical trials: a start in setting international standards.

Bottomley A, Pe M, Sloan J, Basch E, Bonnetain F, Calvert M, Campbell A, Cleeland C, Cocks K, Collette L, Dueck AC, Devlin N, Flechtner HH, Gotay C, Greimel E, Griebsch I, Groenvold M, Hamel JF, King M, Kluetz PG, Koller M, Malone DC, Martinelli F, Mitchell SA, Moinpour CM, Musoro J, O'Connor D, Oliver K, Piault-Louis E, Piccart M, Pimentel FL, Quinten C, Reijneveld JC, Schürmann C, Smith AW, Soltys KM, Taphoorn MJB, Velikova G, Coens C; Setting International Standards in Analyzing Patient-Reported Outcomes and Quality of Life Endpoints Data (SISAQOL) consortium.

Lancet Oncol. 2016 Nov;17(11):e510-e514. doi: 10.1016/S1470-2045(16)30510-1. Epub 2016 Oct 18. Review.

41.

Impact of neurocognitive deficits on patient-proxy agreement regarding health-related quality of life in low-grade glioma patients.

Ediebah DE, Reijneveld JC, Taphoorn MJ, Coens C, Zikos E, Aaronson NK, Heimans JJ, Bottomley A, Klein M; EORTC Quality of Life Department and Patient Reported Outcome and Behavioral Evidence (PROBE).

Qual Life Res. 2017 Apr;26(4):869-880. doi: 10.1007/s11136-016-1426-z. Epub 2016 Oct 15.

42.

Temozolomide chemotherapy versus radiotherapy in high-risk low-grade glioma (EORTC 22033-26033): a randomised, open-label, phase 3 intergroup study.

Baumert BG, Hegi ME, van den Bent MJ, von Deimling A, Gorlia T, Hoang-Xuan K, Brandes AA, Kantor G, Taphoorn MJB, Hassel MB, Hartmann C, Ryan G, Capper D, Kros JM, Kurscheid S, Wick W, Enting R, Reni M, Thiessen B, Dhermain F, Bromberg JE, Feuvret L, Reijneveld JC, Chinot O, Gijtenbeek JMM, Rossiter JP, Dif N, Balana C, Bravo-Marques J, Clement PM, Marosi C, Tzuk-Shina T, Nordal RA, Rees J, Lacombe D, Mason WP, Stupp R.

Lancet Oncol. 2016 Nov;17(11):1521-1532. doi: 10.1016/S1470-2045(16)30313-8. Epub 2016 Sep 27.

43.

Health-related quality of life in patients with high-risk low-grade glioma (EORTC 22033-26033): a randomised, open-label, phase 3 intergroup study.

Reijneveld JC, Taphoorn MJB, Coens C, Bromberg JEC, Mason WP, Hoang-Xuan K, Ryan G, Hassel MB, Enting RH, Brandes AA, Wick A, Chinot O, Reni M, Kantor G, Thiessen B, Klein M, Verger E, Borchers C, Hau P, Back M, Smits A, Golfinopoulos V, Gorlia T, Bottomley A, Stupp R, Baumert BG.

Lancet Oncol. 2016 Nov;17(11):1533-1542. doi: 10.1016/S1470-2045(16)30305-9. Epub 2016 Sep 27.

PMID:
27686943
44.

Seizure control as a new metric in assessing efficacy of tumor treatment in low-grade glioma trials.

Avila EK, Chamberlain M, Schiff D, Reijneveld JC, Armstrong TS, Ruda R, Wen PY, Weller M, Koekkoek JA, Mittal S, Arakawa Y, Choucair A, Gonzalez-Martinez J, MacDonald DR, Nishikawa R, Shah A, Vecht CJ, Warren P, van den Bent MJ, DeAngelis LM.

Neuro Oncol. 2017 Jan;19(1):12-21. doi: 10.1093/neuonc/now190. Epub 2016 Sep 20. Review. Erratum in: Neuro Oncol. 2017 Feb 1;19(2):304.

45.

Accurate Delineation of Glioma Infiltration by Advanced PET/MR Neuro-Imaging (FRONTIER Study): A Diagnostic Study Protocol.

Verburg N, Pouwels PJ, Boellaard R, Barkhof F, Hoekstra OS, Reijneveld JC, Vandertop WP, Wesseling P, de Witt Hamer PC.

Neurosurgery. 2016 Oct;79(4):535-40. doi: 10.1227/NEU.0000000000001355.

PMID:
27479710
46.

Evaluation of potential circulating biomarkers for prediction of response to chemoradiation in patients with glioblastoma.

van Linde ME, van der Mijn JC, Pham TV, Knol JC, Wedekind LE, Hovinga KE, Aliaga ES, Buter J, Jimenez CR, Reijneveld JC, Verheul HM.

J Neurooncol. 2016 Sep;129(2):221-30. doi: 10.1007/s11060-016-2178-x. Epub 2016 Jul 21.

47.

Prognostic value of the S100B protein in newly diagnosed and recurrent glioma patients: a serial analysis.

Holla FK, Postma TJ, Blankenstein MA, van Mierlo TJM, Vos MJ, Sizoo EM, de Groot M, Uitdehaag BMJ, Buter J, Klein M, Reijneveld JC, Heimans JJ.

J Neurooncol. 2016 Sep;129(3):525-532. doi: 10.1007/s11060-016-2204-z. Epub 2016 Jul 11.

48.

[Do not allow the patient immediate access to test results].

Reijneveld JC.

Ned Tijdschr Geneeskd. 2016;160:D545. Review. Dutch.

PMID:
27299500
49.

Preoperative evaluation using magnetoencephalography: Experience in 382 epilepsy patients.

Nissen IA, Stam CJ, Citroen J, Reijneveld JC, Hillebrand A.

Epilepsy Res. 2016 Aug;124:23-33. doi: 10.1016/j.eplepsyres.2016.05.002. Epub 2016 May 10.

PMID:
27232766
50.

Psycho-oncology.

Reijneveld JC, Armstrong TS.

Handb Clin Neurol. 2016;134:305-13. doi: 10.1016/B978-0-12-802997-8.00018-9. Review.

PMID:
26948362

Supplemental Content

Loading ...
Support Center